Modular Medical

What Modular Medical does

Modular Medical, Inc. (NASDAQ: MODD) is a publicly traded medical device company developing insulin delivery technology for adults with insulin-dependent diabetes. Founded in 2015 by Paul DiPerna, the company became publicly traded via a reverse merger in 2017 and is headquartered in San Diego, California. Its core products are the MODD1 insulin pump and the newly FDA-cleared Pivot tubeless insulin patch pump — a two-part removable system with a 3 mL reservoir that requires no battery recharging and supports smartphone connectivity for data sharing with care teams. The Pivot is the second fully electronic, tubeless insulin pump on the U.S. market, designed around micro-pumping technology protected by an IP portfolio of over 70 patents.

The company's business model is hardware sales of the Pivot pump and recurring disposable cartridges and infusion sets, distributed through a phased rollout to high-volume endocrinology practices supplemented by a direct-to-patient education and demand-generation website (PivotPump.com). It targets the 'almost-pumper' segment — the roughly 70% of insulin-dependent U.S. adults currently on multiple daily injections who have not adopted pump therapy — addressing a market the company sizes at approximately $3 billion within an $8 billion global insulin pump opportunity. Pricing is quote-based and not publicly disclosed.

As of mid-2026, Modular Medical is in transition from development-stage to commercial-stage following the Pivot's FDA 510(k) clearance in April 2026 and first commercial shipments in June 2026. Revenue is not yet disclosed, the company is unprofitable, and it has funded operations through multiple post-IPO equity offerings totaling approximately $34 million across 2024-2026. Geographic expansion to Europe is being prepared via CE Mark submission and ISO 13485 certification with BSI, targeted for early 2027, supported by a newly appointed Head of International Operations.

Name

Modular Medical

Legal name

Modular Medical, Inc.

Website

https://modular-medical.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Modular Medical (NASDAQ: MODD) is a San Diego-based medical device company developing tubeless insulin patch pumps, including the FDA-cleared Pivot system, targeting U.S. adults with diabetes on multiple daily injections who have not adopted pump therapy. Revenue model is hardware and disposable sales via endocrinology practices and a direct-to-patient site.

Ownership category

akta.pro rank

Product category

Insulin Delivery Devices / Diabetes Management Hardware

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)

akta.pro secondary industry

Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE)

Keywords

• Insulin pump devices
• Diabetes management
• Drug delivery technology
• Tubeless insulin pump
• Medical device manufacturing

Headquarters

HQ city

Escondido

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pivot Tubeless Insulin Patch Pump Sales: The company generates revenue from the sale of its Pivot tubeless insulin patch pump devices and associated disposable cartridges and infusion sets. Commercial availability began June 2026 following FDA 510(k) clearance, marking transition from development-stage to revenue-generating commercial business.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Modular Medical designs, develops, and manufactures insulin delivery devices — primarily the Pivot tubeless insulin patch pump (FDA-cleared April 2026, commercial availability June 2026) and the MODD1 insulin pump — for adults with insulin-dependent diabetes who are transitioning from multiple daily injections to pump therapy. The company sells the pump hardware along with disposable cartridges and infusion sets, targeting the "almost-pumper" segment that finds traditional pumps too complex or costly.

Product overview

Modular Medical offers two insulin delivery products: the MODD1 insulin pump and the Pivot tubeless insulin patch pump. The MODD1 is designed for simplicity to facilitate transition from manual injections, with data sharing capabilities for care teams. The Pivot is a newer, FDA-cleared tubeless patch pump featuring a removable two-part design with a 3 mL reservoir that requires no battery recharging. The Pivot represents the company's transition from development-stage to commercial-stage following its June 2026 launch.

Differentiator

Problem solved

Functional benefit

Brands

• MODD1: Insulin pump designed for those who want to remove complicated technology and allow for a smooth transition from manual injections.
• Pivot

Products and services

• Pivot Tubeless Insulin Patch Pump A fully electronic, tubeless insulin patch pump featuring a removable two-part design with a 3 mL reservoir that requires no battery recharging. It is the second fully electronic, tubeless insulin pump available in the U.S. market, targeting the estimated 70% of insulin-dependent adults on multiple daily injections who have not adopted pump therapy. Smartphone connectivity enables data tracking and sharing with care teams.
• MODD1 Insulin Pump An insulin pump designed for simplicity, removing complicated technology to allow for a smooth transition from manual injections. It facilitates data sharing with care teams and targets insulin-dependent adults seeking a less complex pump option.

Quantifiable outcome

• Over 6,000 cartridges manufactured in initial production run
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• David Bosshard (Head of International Operations)coreOthers · 3 November 2025David Bosshard appointed as Head of International Operations to drive global expansion of Modular Medical's products, including CE Mark certification and international commercialization.
• BSI (Notified Body)coreTechnology or Integration · 28 October 2025BSI completed Stage 1 ISO 13485:2016 audit for Modular Medical's Pivot insulin delivery system as part of CE Mark certification process. Stage 2 audit planned for early 2026 with CE technical documentation review ongoing for European market launch.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Insulet Corporation: Manufacturer of the Omnipod tubeless insulin patch pump, the established market leader and only other fully electronic tubeless patch pump on the U.S. market prior to Pivot. Directly competes in the same product category, customer segment, and distribution channel.
• Tandem Diabetes Care: Manufacturer of the t:slim X2 insulin pump, founded on technology co-invented by Modular Medical's founder Paul DiPerna. Operates in the same U.S. insulin pump market with overlapping endocrinology prescriber channels.
• Ypsomed: Swiss manufacturer of the mylife YpsoPump and YpsoPump patch-style insulin pump. Competes in the same 'simple-to-use' insulin pump category and is pursuing U.S. market entry, making it a direct strategic comparable.

Broad incumbents

• Medtronic Diabetes: Incumbent insulin pump manufacturer (MiniMed series) with broad diabetes portfolio including CGM and AID systems. Competes in the same endocrinology-prescribed insulin pump space with substantially greater scale and payor leverage.
• Embecta: Spun off from BD, Embecta is the leading manufacturer of insulin pen needles and injection supplies — serving the same insulin-dependent diabetes patient population, particularly the 'almost-pumper' multiple daily injection segment Modular Medical targets.
• Roche Diabetes Care: Incumbent diabetes care provider (Accu-Chek brand) offering insulin pumps and blood glucose monitoring systems. Competes broadly in insulin-dependent diabetes management across multiple geographies.
• Abbott Diabetes Care: Manufacturer of FreeStyle Libre CGM systems and broader diabetes care portfolio. Serves the same insulin-dependent diabetes patient population with overlapping care team relationships.

Emerging players

• Beta Bionics: Developer of the iLet bionic pancreas, an insulin-only and dual-hormone automated insulin delivery system. Competes in adjacent diabetes management technology with overlapping endocrinology prescriber base.
• MannKind Corporation: Markets Afrezza inhaled insulin and the V-Go wearable basal insulin delivery patch. V-Go is a tubeless patch insulin device directly comparable to Pivot's wearable delivery approach.

Others

• Dexcom: Leading CGM manufacturer integrated with most modern insulin pumps (including Omnipod 5 and Tandem t:slim X2). Functions as an ecosystem partner and adjacent technology in the same diabetes care workflows Modular Medical's Pivot targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/modular-medical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds10 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Modular Medical